ClinicalTrials.gg
Status unknownNCT02817932Updated Jun 29, 2016

A Study of Pharmacokinetics and Safety of Ranolazine PR in Healthy Korean and Caucasian Male Subjects

A Phase 1 interventional study of Ranolazine in Healthy Male Individuals, sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-29.

Sponsored by A.Menarini Asia-Pacific Holdings Pte Ltd (part of Menarini Group) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
Male
01

Study summary

The purpose of this study is:

To assess the pharmacokinetic profile and safety of ranolazine PR in healthy Korean and Caucasian volunteers after oral administration of Ranolazine at the doses of 375, 500, 750mg after single and repeated oral administrations.

Read the detailed description

Ranolazine is an antianginal drug that exerts its effects by inhibition of the late sodium current in cardiac cells. This action reduces intracellular sodium accumulation and consequently decreases intracellular calcium overload which is expected to reduce myocardial stiffness, oxygen consumption and ATP utilization and improve blood flow to the microvasculature.These effects of ranolazine do not depend upon reductions in heart rate or blood pressure or vasodilation.

Ranolazine PR, approved for treatment of chronic angina in 56 countries and currently marketed in 21 countries including the US shows clinical efficacy and tolerability in the proposed therapeutic dose range from 375 mg to 750mg. Factors that may affect ranolazine pharmacokinetics including demographics, drug-drug interactions, disease state, CYP2D6 metabolizer genotype status and impaired renal or hepatic functions have been studied. The relationship between ranolazine plasma concentration and clinical effects has been also well-established. This PK study has been designed as a bridging study for Ranolazine PR registration in Korea.

02

Conditions studied

  • Healthy Male Individuals
03

In context

Lead sponsor

A.Menarini Asia-Pacific Holdings Pte Ltd is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

First submitted after A.Menarini Asia-Pacific Holdings Pte Ltd became part of Menarini Group.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult Korean or Caucasian males, 19 - 45 years of age

    • Korean subjects: first generation of Korean subject born in Korea, both parents and the four grandparents must be of Korean origin. Proof of Korean ethnicity will be documented by medical interview and appropriate materials (e.g. Korean passport, Korean resident card) will be retained in the subject's folder
    • Caucasian subjects: first generation of Caucasian subject, both parents and the four grandparents of European descent. Documentation of ethnicity will be by medical interview and by appropriate materials (e.g. passport, birth certificate(if not available, a signed affirmation by the subjects)) will be retained in the subject's folder
  2. Subjects weighing ≥ 50 kg with between 18 and 27 kg/m2 (inclusive) at screening visit
  3. Subjects with no abnormal findings as determined by physical examination, , medical history, or clinical laboratory test results
  4. Subjects who agreed to voluntarily participate in this study and comply with all the study requirements by signing form after being informed of the nature of this study and understanding all aspects of this study

Exclusion criteria

Exclusion Criteria:

  1. History of gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorder
  2. Surgery of the gastrointestinal tract that could interfere with kinetics of the study drug
  3. Relevant chronic or acute infections
  4. History of relevant allergy/ (including allergy to the trial medication or its )
  5. Administration of any products within 3 months from the first dose of the study drug (ranolazine PR)
  6. History of participating other BE study or clinical trial within 3 months from the first dose of the study drug(ranolazine PR)
  7. Any of the following vital sign abnormalities

    • Systolic blood pressure: \<90 mmHg or >140 mmHg
    • Diastolic blood pressure: \<50 mmHg or > 90 mmHg
    • Pulse rate: \<50 bpm or >90 bpm
  8. Any of the following abnormalities

    • PR > 210 msec
    • QRS complex > 120 msec
    • > 430 msec
  9. Any finding in the physical examination deviating from normal and judged clinically significant by the investigator
  10. Any laboratory value outside of the reference range that the investigator considers to be of clinical significance
  11. Subjects who have donated blood or received blood transfusion within 90 days of participating in this study
  12. Subjects who are positive for , , VDRL and
  13. Subjects who showed positive result in alcohol and drug abuse tests
  14. Subjects who have smoked over 10 cigarettes until 90 days prior to the study initiation or who is not able to stop smoking throughout the hospitalization period
  15. Subjects who took prescribed medications within 14 days or over-the-counter (OTC) medications within 7 days prior to the first dose of the study drug (ranolazine PR) or who have to take these medications during the study period
  16. Subject who judged not eligible for study participation by investigator
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Group 1 (Korean, 375 mg)

    Group 1 (Korean, 375 mg): Ranolazine PR 375 mg

    Drug: Ranolazine

  • Experimental
    Group 2 (Korean, 500 mg):

    Group 2 (Korean, 500 mg): Ranolazine PR 500 mg

    Drug: Ranolazine

  • Experimental
    Group 3 (Korean, 750 mg):

    Group 3 (Korean, 750 mg): Ranolazine PR 750 mg

    Drug: Ranolazine

  • Experimental
    Group 4 (Caucasian, 375mg)

    Group 4 (Caucasian, 375mg) : Ranolazine PR 375 mg

    Drug: Ranolazine

  • Experimental
    Group 5 (Caucasian, 750mg)

    Group 5 (Caucasian, 750mg) : Ranolazine PR 750 mg

    Drug: Ranolazine

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic assessment

    Area under the plasma concentration versus time curve (AUC)

    Time frame: Up to 5 days

  2. Pharmacokinetic Assessment

    Plasma concentration (maximum,through, average)

    Time frame: Up to 5 days

  3. Pharmacokinetic Assessment

    Tmax

    Time frame: Up to 5 days

  4. Pharmacokinetic Assessment

    Half-life

    Time frame: Up to 5 days

Secondary outcomes

  1. Number of participants with treatment-related adverse events assessed using MedDRA

    Assessment based on reported symptoms, physical examination, vital signs, adverse events, ECGs, laboratory test results

    Time frame: 5 days

07

Study locations

1 of 1 sites recruiting
  • Seoul National University Hospital
    Seoul, Korea, Republic of
    Recruiting
    • In-Jin Jang, MD · Contact+82 2 2072 1910
08

References and documents

Publications

  • Yoo H, Lee SW, Yoon DY, Yoon SH, Cho JY, Yu KS, Jang IJ, Lee S. Pharmacokinetics and Safety of Extended-release Ranolazine in Korean and White Healthy Subjects. Clin Ther. 2021 Mar;43(3):526-534.e4. doi: 10.1016/j.clinthera.2021.01.005. Epub 2021 Jan 29. PubMed 33518355 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Jul 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2016
First posted
Jun 29, 2016
Start
Mar 2016
Primary completionEst.
Jul 2016
CompletionEst.
Oct 2016
Last update
Jun 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02817932
Responsible party
Sponsor
First posted
Jun 29, 2016
Start date
Mar 2016
Primary completion
Jul 2016 (estimated)
Completion
Oct 2016 (estimated)
Last update
Jun 29, 2016

Study contacts

In-Jin Jang, MD
Contact
: +82 2 2072 1910
In-Jin Jang, MD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion